Aytu Biopharma Inc
F:AY20
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aytu Biopharma Inc
F:AY20
|
US |
|
Naturgy Energy Group SA
F:GANA
|
ES |
|
V
|
voestalpine AG
XMUN:VAS
|
AT |
|
ASR Nederland NV
F:A16
|
NL |
|
T
|
Texas Instruments Inc
XMUN:TII
|
US |
|
C
|
CSX Corp
XMUN:CXR
|
US |
|
S
|
Scor SE
DUS:SDRC
|
FR |
|
C
|
Casio Computer Co Ltd
XMUN:CAC1
|
JP |
|
C
|
Coca Cola HBC AG
F:C0Q
|
CH |
|
M
|
Myriad Genetics Inc
F:MYD
|
US |
|
F
|
freenet AG
F:FNTN
|
DE |
|
S
|
Sonos Inc
F:8SO
|
US |
|
B
|
Basf Se
SWB:BAS
|
DE |
Wall St Price Targets
AY20 Price Targets Summary
Aytu Biopharma Inc
According to Wall Street analysts, the average 1-year price target for AY20 is 12.146 EUR with a low forecast of 9.02 EUR and a high forecast of 18.755 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AY20's stock price target?
Price Target
12.146
EUR
According to Wall Street analysts, the average 1-year price target for AY20 is 12.146 EUR with a low forecast of 9.02 EUR and a high forecast of 18.755 EUR.
What is the Revenue forecast for Aytu Biopharma Inc?
Projected CAGR
13%
Over the last 9 years, the compound annual growth rate for Revenue has been 43%. The projected CAGR for the next 3 years is 13%.
What is the Operating Income forecast for Aytu Biopharma Inc?
Projected CAGR
17%
The compound annual growth rate for Operating Income over the next 3 years is 17%.
